Technical analysis of Pliant Therapeutics, Inc. (PLRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
Price Performance
| 1 month | -6.96% |
| 3 months | -7.76% |
| Year-to-date | -12.30% |
| 1 year | -26.71% |
| 3 years | -93.47% |
| 5 years | -94.13% |
52-Week Range
| 52-week High | $1.95 |
| 52-week Low | $1.02 |
| Avg Volume (90d) | 497K |
Technical Indicators
| SMA 50 | $1.11 |
| SMA 200 | $1.21 |
| Beta | 1.25 |
| 30-day Volatility (annualised) | 41.6% |
| Price vs SMA 50 | -3.3% |
| Price vs SMA 200 | -11.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.68 | |
| 2025-11 | $1.61 | -4.2% |
| 2025-12 | $1.22 | -24.2% |
| 2026-01 | $1.21 | -0.8% |
| 2026-02 | $1.30 | +7.4% |
| 2026-03 | $1.26 | -3.1% |
| 2026-04 | $1.22 | -3.2% |
| 2026-05 | $1.26 | +3.3% |
| 2026-06 | $1.14 | -9.5% |
| 2026-07 | $1.04 | -8.8% |
| 2026-08 | $1.10 | +5.8% |
| 2026-09 | $1.07 | -2.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.07 |
| Market Cap | $66M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | -0.86 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.20 |
| Current Ratio | 9.90 |